Engineering the
Future of Human
Health
Derisking the biotech frontier through expert scientific due diligence and diversification.
Our Thesis
The biology of aging is now tractable
Biology fails before we do. Over 4 million people need organ transplants annually — fewer than 5% receive one. Chronic diseases and aging drive tissue degeneration, and no integrated system exists to regenerate, replace, and maintain human health.
We are building that system. Longevity Venture Fund I targets a $250B+ market across regenerative medicine, cell therapies, organ transplantation, longevity medicine, and medical tourism.
We back founders at the earliest stages — writing conviction checks, taking board seats, and staying committed through the full company-building journey.
We started the fund with three companies that are better together and ready to add new and innovative strategies to derisk biotech investing.
We are initially raising $20 million to deploy across our founding portfolio and pipeline of breakthrough longevity opportunities.
"Regeneration when possible. Replacement when necessary. Longevity for everyone."
— LVF I Investment Committee
Focus Areas
Six frontiers defining the longevity revolution
Epigenetic Reprogramming
Partial cellular reprogramming using Yamanaka factors and next-generation approaches to reverse epigenetic age, restore tissue function, and potentially extend healthspan by decades.
Clinical Delivery & Medical Tourism
Capitalizing on the rapidly growing global medical tourism market by connecting patients to cutting-edge longevity treatments abroad — enabling clinical delivery of therapies not yet available domestically at scale.
AI-Driven Drug & Advanced Cellular Therapy
Machine learning and large biological models accelerating the identification of novel longevity targets, compound screening, and clinical trial design — combined with next-generation cellular therapies engineered for precision and scale.
Advanced Transplantation Strategies
Pioneering the next frontier in organ transplantation — from xenotransplantation using gene-edited animal organs to 3D bioprinting of patient-specific tissues, expanding the supply of transplantable organs and reducing immune rejection.
Peptide Development
Advancing the discovery and development of therapeutic peptides — highly targeted, bioactive molecules that modulate aging pathways, tissue repair, metabolic function, and cellular signaling with precision.
iPSC Differentiation & Manufacturing
Developing autologous and allogeneic Induced Pluripotent Stem Cell (iPSC) differentiation protocols and scalable manufacturing processes to produce patient-ready cell therapies that combat chronic diseases and restore organ function.
Portfolio
Backing the builders
rewriting biology
Three initial investments across iPSC cell banking, xenotransplantation, and regenerative medicine clinics.
Cellarion
Life Beyond Limits
Personalized iPSC biobank platform converting blood samples into an immortal archive of your cellular life, enabling future regenerative therapies across 10+ disease areas.
CrofaBiotech
Genetically Edited Organs for Human Transplantation
CRISPR/Cas9-based gene editing platform producing human-compatible organs from genetically modified pigs (xenotransplantation), targeting the 4M+ patients annually who need a transplant.
Renue
World-Class Regenerative Medical Centre
World-class regenerative medical centre delivering stem cell therapies, anti-aging treatments, and personalized regenerative medicine to patients globally.
3 investments made. Actively seeking more. Founders — pitch us.
Vertical Integration
Science → Manufacturing
→ Delivery → Scale
Cellarion
Science & Manufacturing
Designs personalized iPSC-derived therapies. High-margin, recurring biobank revenue with 10+ cell differentiation pathways.
CrofaBiotech
Organ Replacement
Replaces failing organs with gene-edited xenotransplants. CrofaPig® reduces immune recognition by 80%.
Renue
Clinical Delivery
Delivers regenerative therapies to patients globally. World-class medical centre with active clinical operations and medical tourism programs.
Combining operational biotech expertise with disciplined private equity capital to accelerate vertical integration and deliver outsized returns in longevity.
The Team
Deep science,
proven judgment
Steve Anderson
Co-Chief Investment Officer
Seasoned PE Executive, decades as a senior executive of a publicly traded broker-dealer/investment manager with $130B+ in AUM. Recognized thought leader in biotech, strategic finance, operations, and market expansion with extensive public and private board experience. Founder of RENUE, a leading private clinic specializing in Medical Tourism and Stem Cell therapies.
Bradley Robinson
Co-Chief Investment Officer
Founder of pioneering personalized medicine and regenerative therapy companies. CEO of Cellarion, with expertise in cellular therapy development, diagnostics, and commercializing innovative biotech solutions. Key driver in advancing iPSC-based therapies and translational execution across multiple medical device and biotech ventures.
Scientific Advisory Board
Pedro Gutiérrez-Castrellón, MD, PhD, MBA
Chief Medical Officer, Cellarion · CEO, Elemental Translational Research
Jonathan Lakey, PhD, MSM
Chief Science Officer, Cellarion · Professor Emeritus, UC Irvine
Zijiang (Jay) Yang, PhD
Founder & CEO, BetaCure · Harvard Medical School / MIT
Prof. Paul de Vos
Full Prof. Immunoendocrinology · Biocompatibility & Pancreatic Islets
Krista Casazza, PhD, RD, CSSD
Nutritional Biochemistry · Metabolic & Neurodegenerative Disease
Adrian Angel Mutto, PhD
CLO Biotech · National University of San Martín
Dr. Adrián Abalovich
CSO, CrofaBiotech · Xenotransplantation Pioneer · INCUCAI Regulatory Committee
Muhammad M. Mohiudin, MD, DSc
Cardiac Xenotransplantation, Univ. of Maryland · Nature Top 10 (2022)
Daniel de Florian, PhD
CIAI Argentina · UNSAM · CERN Theory Division
Marcelo Grabois
ITERA · Intellectual Property & Competitive Intelligence
Dr. Carolina Bluguermann
CONICET Assistant Researcher · National University of General San Martín (UNSAM) · Cell Technology & Stem Cells
Scientific advisors drawn from Cellarion, CrofaBiotech, and Renue portfolio companies.
Industry Pulse
Latest breakthroughs from our portfolio and the broader longevity ecosystem.
CrofaBiotech confirmed that Bety is companies first 3KO gene edited pig.
CrofaBiotech, a portfolio company of Longevity Venture Fund I, LLC, today confirmed that “Bety,” a gene-edited cloned pig produced at the company’s programme in Argentina, carries functional knockouts of all three genes responsible for the major carbohydrate xenoantigens that prevent transplantation of pig organs into humans. Testing of kidney and heart tissue confirmed the absence of all three antigens, measured against wild-type controls in which all three were present. The result places CrofaBiotech among a small group of programmes worldwide — and, to the company’s knowledge, the first in Latin America — to have produced and validated a triple-knockout (3KO) pig. It is the enabling step for the company’s first-in-human clinical trial, currently slated for the middle of next year.
Longevity Venture Fund I Acquires 30% Stake in XenoBlood, LLC in $500,000 Seed Investment
Longevity Venture Fund I (“LVF I” or “the Fund”), a private fund investing in regenerative medicine and longevity businesses, today announced a seed investment in XenoBlood, LLC, a preclinical biotechnology company developing genetically engineered porcine red blood cells. Under the agreement, LVF I will invest $500,000 in stage-gated tranches for a 30% fully diluted ownership stake, implying a post-money valuation of approximately $1.67 million.
CrofaBiotech Announces Birth of Latin America's First 3-Gene Modified Pig for Xenotransplantation
The "CrofaPig" represents a historic milestone in the race to solve the global organ shortage crisis, positioning CrofaBiotech as a regional leader in xenotransplantation research.
Cellarion — 5 iPSC Clinical Trials Planned to be Initiated in Q2 & Q3 2026
Cellarion is progressing its iPSC biobank platform with 5 clinical trials planned for Q2 and Q3 2026, targeting $67M in Year 5 revenue — one of the most capital-efficient iPSC programs in the industry.
Weekly Competitor News Sweep
BlueRock advanced bemdaneprocel to a registrational Phase III — the first for any pluripotent-stem-cell-derived therapy in Parkinson's. TreeFrog presented preclinical data showing functional motor recovery in ~13 weeks.
RENUE Medical Centre to Build cGMP iPSC Production Laboratory
RENUE will become one of only two facilities in the world treating patients with iPSCs. The state-of-the-art laboratory in Nuevo Vallarta will manufacture clinical-grade iPSCs in partnership with Cellarion.
Get In Touch
Ready to rewrite
the biology of aging?
Whether you're a founder building at the longevity frontier or an investor interested in the fund — we want to hear from you.
Scottsdale, Arizona
